Business Context and Reporting Period
Molecular Partners AG (MOLN) is a clinical-stage biotech company developing DARPin therapeutics, primarily focusing on oncology. This Form 6-K filing covers the unaudited condensed consolidated interim financial results for the three and six months ended June 30, 2025, and includes a strategic update issued on August 25, 2025.
Key Financial Metrics (H1 2025)
| Metric | Value (CHF) |
|---|---|
| Total Revenues | 0.0 million |
| Operating Loss | (33.5) million |
| Net Loss | (37.2) million |
| Net Loss Per Share | (1.00) |
| Net Cash Used in Operating Activities | (30.2) million |
| Cash and Short-Term Deposits | 114.5 million |
| Total Debt | 0.0 million (Debt-free) |
| Shareholders' Equity | 106.7 million |
Material Changes vs. Prior Period (H1 2024)
- Revenue: Decreased by CHF 4.3 million to zero. The prior period revenue was solely attributable to the Novartis collaboration, which concluded in H2 2024.
- Operating Expenses: Decreased by CHF 2.7 million (7%) to CHF 33.5 million. This reduction was driven by lower R&D costs (down CHF 4.6 million) and SG&A costs (down CHF 0.7 million), partially offset by CHF 2.6 million in restructuring expenses.
- Net Loss: Increased by CHF 10.8 million to CHF 37.2 million, primarily due to the loss of revenue and a shift from a net financial gain in 2024 to a net financial loss of CHF 3.7 million in 2025 (driven by foreign exchange fluctuations).
- Cash Position: Cash and short-term deposits decreased by CHF 44.6 million year-over-year to CHF 114.5 million.
- Headcount: Full-time equivalents (FTE) decreased by 8.9 to 153.0, following a strategic review and workforce reduction of up to 40 positions (~24% of total).
Guidance, Outlook, and Management Commentary
- Financial Outlook: For the full year 2025, the Company expects total expenses of CHF 55–65 million (at constant exchange rates), including approximately CHF 7 million in non-cash costs. Management projects the company will be funded into 2028, extending beyond prior guidance of 2027, due to cost efficiencies.
- Program Updates:
- MP0712 (Radio-DARPin): IND filing expected in Q3 2025 for small cell lung cancer; Phase 1 initiation planned for 2025 with initial data in H1 2026.
- MP0533 (T Cell Engager): Phase 1/2a trial for AML shows promising response rates with accelerated dosing. Protocol amended for Cohorts 9 and 10 to enhance exposure; initial data expected Q4 2025.
- Partnerships: Expanded strategic radiotherapy partnership with Orano Med to co-develop up to ten programs.
- Management Changes: Martin Steegmaier, Ph.D., appointed as Chief Scientific Officer (CSO), effective October 1, 2025.
- Risks: The Company faces liquidity risks due to a lack of consistent positive operating cash flow and exposure to foreign exchange rate fluctuations (CHF, EUR, USD).
Investor Verification Checklist
- Verify the timeline for the MP0712 IND filing and Phase 1 initiation in 2025.
- Monitor the Q4 2025 data readout for MP0533 Cohort 9 to assess the efficacy of the amended dosing protocol.
- Confirm the execution of the workforce reduction and its impact on the projected cash runway into 2028.
- Review the status of the Orano Med partnership expansion and potential future milestone payments.
- Assess the impact of foreign exchange fluctuations on future financial results given the Company's natural hedging policy.